What’s New in the Canadian Group Benefits Landscape
(1) National Pharmacare (Plan NP) Is Live in BC — But Federal Expansion Is in Doubt
As of March 1, 2026, BC residents can access diabetes medications, hormone replacement therapy, and contraceptives at no cost at the pharmacy, with private plans paying only the gap. However, Ottawa’s Spring 2026 Economic Update has effectively halted national expansion – signalling no new federal funding and leaving provinces to fund future coverage on their own.
Source: Government of Canada, National Pharmacare
(2) Mental Health Is Costing Canadian Employers $110 Billion Annually
A new report confirms Canadian employers are bearing $110B/year in costs tied to mental health – driven by lost productivity, disability leave, and workplace accommodations – representing the largest share of a $180B national economic burden.
Source: Benefits Canada, Mental-health issues costing Canadian employers $110 billion annually: report
(3) 75% of Employers Are Redesigning Their Benefits Plans in 2026
Cost and profitability pressures are pushing three-quarters of Canadian employers to make changes to their benefits packages. The challenge: balancing cost containment with competitive coverage across a workforce that now spans five generations.
Source: HUB International, Long-term planning and innovative strategies will help turn employee benefits into a competitive advantage.
(4) GLP-1 Drug Coverage (Ozempic/Wegovy) Is Expanding Fast
31% of Canadian employers now cover GLP-1 drugs for both diabetes AND weight loss, up sharply from 17% in 2024. Meanwhile, generic Ozempic is expected to reduce costs and open the door for wider coverage.
Source: IFEBP, GLP-1 Drug Coverage Continues to Rise in Canada.
(5) Inclusive Benefits Are Expanding to Cover Women’s Full Health Journey
Canadian employers are redesigning benefits to support women across every life stage — from fertility and family planning through to menopause and beyond. Companies like PepsiCo Canada have increased fertility treatment maximums to $10,000–$15,000. Health Canada has committed $1.93 million to its “Beyond the Hot Flash” initiative for evidence-based menopause care.
Source: HR Reporter, More Canadian employers offering fertility, gender affirmation, obesity-medication benefits
(6) Extended Health Benefit Costs Are Rising
Inflation continues to squeeze plan budgets. Extended health benefit renewal increases are expected to further rise in 2026, driven by drug costs, paramedical inflation, and increased utilization post-pandemic.
Source: CPA BC, Inflation update 2026: What’s in store for employee benefits plans
(7) The Shift from Mental Health Crisis Response to Mental Fitness
Canadian employers are moving beyond reactive EAP programs toward proactive “mental fitness”, embedding resilience training, no-meeting days, mental health check-in rituals, and manager upskilling into everyday culture.
Source: Policy Advisor, 7 Employee Benefits Trends Transforming Group Insurance in Canada (2026)
(8) Financial Wellness Is Now a Core Benefits Strategy
After years of affordability pressure, financial stress now ranks among the top drivers of poor mental health in Canadian workplaces. Employers are responding with debt counselling, pay flexibility, and financial literacy programs — not as a perk, but as a health investment.
Source: Insurance Business, Financial stress emerges as a key health risk in Canadian workplaces: report
(9) Health Care Spending Accounts Are Surging — Now at 47%
HSA adoption has jumped from 40% (2024) to 47% (2026), reflecting growing demand for flexible, personalized coverage. Plan members (especially younger generations) expect consumer-grade customization.
Source: Quickcard HSA, Health Spending Accounts (HSA) Canada: The 2026 Guide for Employers & Businesses
(10) Biosimilars delivering 25–50% savings vs. originator biologics. RA costs falling despite rising prevalence.
Biosimilars now hold roughly 15-16% of the Canadian biologic market, up from under 5% in 2019 – driven by provincial switching policies and a growing roster of approved alternatives. Continued growth is expected as drugs like Stelara, Eylea, and Xolair biosimilars mature.This means lower drug spend without therapeutic compromise, more predictable benefit plan inflation, and a stronger foundation for sustainable plan design as costly specialty drugs continue to enter the market.
Source: Government of Canada, Canada’s evolving market for biosimilars and what it means for payers